Article

[Hepatocellular carcinoma: resection versus transplantation].

Chirurgische Klinik II-Klinik für Abdominal-, Transplantations- und Gefässchirurgie, Universität Leipzig.
Zentralblatt für Chirurgie (Impact Factor: 1.19). 02/2000; 125(7):624-8. DOI: 10.1055/s-0033-1351783
Source: PubMed

ABSTRACT For decision of adequate surgical therapy and comparison of results differentiation of hepatocellular carcinomas (HCC) in cirrhotic and noncirrhotic livers is important. Liver resection is the treatment of choice for HCC in noncirrhotic liver. Between 4/94 and 8/99 we treated 54 patients with hepatocellular carcinoma (HCC) by subtotal hepatic resection (n = 40) and orthotopic liver transplantation (n = 14). Overall 1- and 3-year survival rates of the resection group were 45 and 25% (median follow up: 3.5 years). One-year survival in the transplantation group was 72% (median follow up: 2.2 years). In patients with HCC in cirrhosis in UICC stage I to III the optimal therapy is a controversial issue. In these patients the results after liver resection are poor due to high operative mortality and recurrence (3-year recurrence-free survival: 30%). Regarding the literature, liver transplantation is the treatment of choice in small (< 3-5 cm, < or = 2 tumors) HCCs arising in cirrhosis with better outcome compared to resection. The data in the literature report 3-year-survival rates after liver transplantation of 60-80%. However, consequent patient selection is necessary for this treatment modality. Due to the limited donor resources liver transplantation is rarely justified in advanced tumors.

0 Followers
 · 
41 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: The benefits of hepatic transplantation (HT) compared with hepatic resection (HR) in treating hepatocellular carcinoma (HCC) in patients with cirrhosis are controversial. The aim of this study was to compare the results of these therapeutic options. The charts of all patients with cirrhosis who underwent HR or HT for HCC between 1997 and 2000 were analyzed. The cohort included 44 patients who underwent HR compared with 65 with HT. All patients in the HR group had Child's A disease, in contrast to the HT group, which included 23% Child's A and 77% Child's B and C patients. Whereas all HT patients spent at least three nights in the intensive care unit, 41% of the HR group never required critical care. Perioperative mortality was 7% in both groups. Pathologic analysis revealed T1/T2 disease in 43% of the HR group compared with 75% of the HT group. After 36 months of follow-up, there was no significant difference in overall survival (57% vs. 66%) or disease-free survival (36% vs. 66%) between the two groups. With overall survival and disease-free survival as the main outcomes, the results of HR versus HT are comparable in Child's A patients with HCC. In this patient subset, HR not only is an effective form of therapy, but is also associated with quicker recovery.
    Annals of Surgical Oncology 12/2002; 9(9):881-6. DOI:10.1007/BF02557525 · 3.94 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Several therapeutic procedures have been proposed as bridging treatments for patients with hepatocellular carcinoma (HCC) awaiting liver transplantation (LT). The most used treatments include transarterial chemoembolization and radiofrequency ablation. Surgical resection has also been successfully used as a bridging procedure, and LT should be considered a rescue treatment in patients with previous HCC resection who experience tumor recurrence or post-treatment severe decompensation of liver function. The aims of bridging treatments include decreasing the waiting list dropout rate before transplantation, reducing HCC recurrence after transplantation, and improving post-transplant overall survival. To date, no data from prospective randomized studies are available; however, for HCC patients listed for LT within the Milan criteria, prolonging the waiting time over 6-12 mo is a risk factor for tumor spread. Bridging treatments are useful in containing tumor progression and decreasing dropout. Furthermore, the response to pre-LT treatments may represent a surrogate marker of tumor biological aggressiveness and could therefore be evaluated to prioritize HCC candidates for LT. Lastly, although a definitive conclusion can not be reached, the experiences reported to date suggest a positive impact of these treatments on both tumor recurrence and post-transplant patient survival. Advanced HCC may be downstaged to achieve and maintain the current conventional criteria for inclusion in the waiting list for LT. Recent studies have demonstrated that successfully downstaged patients can achieve a 5-year survival rate comparable to that of patients meeting the conventional criteria without requiring downstaging.
    World Journal of Gastroenterology 11/2013; 19(43):7515-30. DOI:10.3748/wjg.v19.i43.7515 · 2.43 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The successful management of hepatocellular carcinoma (HCC) requires a multidisciplinary approach, incorporating hepatologists, oncologists, surgical oncologists, transplant surgeons, and radiologists. With improvements in technology and better long-term outcomes data, management strategies for HCC have become more methodical and more successful. This article focuses on some of the most critical advances relating to carcinogenesis, surveillance, and management.
    Surgical Oncology Clinics of North America 04/2014; 23(2):289-311. DOI:10.1016/j.soc.2013.10.006 · 1.67 Impact Factor